GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » Cash per Share

CELU (Celularity) Cash per Share : $0.01 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Celularity Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Celularity's Cash per Share for the quarter that ended in Sep. 2024 was $0.01.

Celularity Cash per Share Historical Data

The historical data trend for Celularity's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celularity Cash per Share Chart

Celularity Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash per Share
4.43 3.00 0.94 0.01

Celularity Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.09 0.02 0.01

Celularity Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Celularity's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=0.227/19.38
=0.01

Celularity's Cash per Share for the quarter that ended in Sep. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=0.133/21.98
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celularity  (NAS:CELU) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Celularity Cash per Share Related Terms

Thank you for viewing the detailed overview of Celularity's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Celularity Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » Cash per Share
Comparable Companies
QNCX BSEM INTS DARE CKPT ICCC RAIN LPTX BYSI BOLT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
170 Park Avenue, Florham Park, NJ, USA, 07932
Website
https://www.celularity.com
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
Executives
Kok Thay Lim director 22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Robert J Hariri director, officer: Chief Executive Officer 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Ling Geoffrey M.d. director C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
Berhad Genting 10 percent owner 24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Adrian Kilcoyne officer: See Remarks 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
John Sculley director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kyle Fletcher officer: General Counsel CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932
Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292
Dean C Kehler director C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Marc Mazur director 31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Bradley Glover director, officer: Chief Technology Officer C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Stephen Brigido officer: Pres, Functional Regeneration C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Anne Jones director, officer: Chief Business Officer C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932